Literature DB >> 10700436

Autologous stem cell transplantation in a case of treatment resistant central nervous system lupus.

E Trysberg1, I Lindgren, A Tarkowski.   

Abstract

This case report describes a young woman with systemic lupus erythematosus starting at 16 years of age and giving rise to severe neurological complications including bilateral opticus neuritis and transverse myelitis. Despite heavy immunosuppression her condition steadily aggravated. At this point it was decided to perform autologous stem cell transplantation. Haematopoietic stem cells were mobilised with cyclophosphamide and granulocyte colony stimulating factor. Enrichment of CD34(+)cells was followed by depletion of peripheral T and B cells. The post-transplantation course was uneventful, and all the neurological deficits improved promptly during the 15 months of follow up. This is the first description of successful autologous stem cell transplantation in a case of life threatening central nervous system lupus.

Entities:  

Mesh:

Year:  2000        PMID: 10700436      PMCID: PMC1753087          DOI: 10.1136/ard.59.3.236

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  3 in total

1.  Use of CD34+ autologous stem cell transplantation in the treatment of children with refractory systemic lupus erythematosus.

Authors:  J Chen; Y Wang; G Kunkel; H Zhao; H Xue; X Xie; L Li; C Xu; L Shen; L Gu
Journal:  Clin Rheumatol       Date:  2005-01-21       Impact factor: 2.980

Review 2.  Hematopoietic stem cell transplantation for systemic lupus erythematosus.

Authors:  Alberto M Marmont du Haut Champ
Journal:  Clin Dev Immunol       Date:  2012-08-30

Review 3.  Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Lea Grote-Levi; Nora Möhn; Kurt-Wolfram Sühs; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Corinna Trebst; Thomas Skripuletz; Martin W Hümmert
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.